- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02810886
Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management (ProsPERo)
Prospective Evaluation of 68Ga-PSMA-ligand PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management
Study Overview
Detailed Description
68Ga-PSMA-ligand PET-CT is a recently developed molecular imaging technique. It is based on the prostate specific membrane antigen (PSMA), a transmembrane protein with a large extracellular domain which is over-expressed on prostate cancer cells surface. Initial experiments used a ligand to the extracellular epitope of PSMA and labelled it with the isotope 68Ga, a positron emitter (68Ga-PSMA-HBED-CC) 5.
Recently published data based on more than 300 patients show recurrence detection rates and tumour to background ratios higher than choline PET-CT, even at low Prostate Specific Antigen (PSA) levels (sensitivity of 70% in PSA<2ng/ml) 6,7. False-positive PSMA findings are not yet reported.
The therapeutic management of biochemical recurrence in prostate cancer depends on the localisation and the extent of the recurrent disease.
In this study, the hypothesis is that 68Ga-PSMA-ligand PET-CT, through its high diagnostic accuracy has a significant impact on the therapeutic management of patients with biochemical recurrence.
Primary objective:
To prospectively evaluate the impact of PSMA-PET/CT on the therapeutic management of patients with biological recurrent prostate cancer and negative, equivocal or oligometastatic disease after routine imaging diagnostic work-up.
The treatment management decision will be recorded at the urologic tumor board (UTB) before and after the PSMA-PET/CT result. Rate of decision change will be calculated.
Secondary objective(s)
- To compare detection rates of PSMA PET/CT and Routine Imaging Workup
- To search for a predictor of a positive PET scan
- To assess diagnostic value of PSMA-PET/CT
- To assess PSA response after targeted treatment for oligometastatic disease.
- To evaluate the delay to start of Androgen Deprivation Therapy (ADT) from the UTB decision.
- To evaluate the time to PSA progression.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old.
- Histologically-proven prostate adenocarcinoma.
Biochemical recurrence (BCR) after local treatment with radical curative intent based on PSA values 1:
- Following Radical Prostatectomy +/- Radiotherapy: a serum PSA increase confirmed by a second PSA measurement higher than the first one with a value of 0.2 ng/mL or more within minimum of one week.
- Following primary Radiotherapy: PSA value of 2 ng/ml above the nadir.
- A continued rise in PSA level despite treatment with curative intent.
Patients with negative, inconclusive or oligometastatic disease on the Routine Imaging Workup and susceptible to be treated with curative radical intent (salvage treatment).
- Routing Imaging Workup exams are accepted when performed within 1 month before PSMA-PET/CT (this includes WB-MRI, prostatic/pelvic MRI, and/or Bone Scintigraphy).
- Patient treatment strategy based on routine diagnostic work-up needs to be recorded after discussion at the Urologic Tumor Board and available before the PSMA PET/CT.
- ECOG performance status ≤ 2
- Signed informed consent prior to any study related procedure.
Exclusion Criteria:
- Previous malignancy other than Prostate Cancer (except basocellular or squamous cell skin cancer).
- Patients treated with palliative chemotherapy or new hormonal therapies like Abiraterone/Enzalutamide.
- PSA rise while on active treatment (LHRH-agonist, LHRH-antagonist, anti-androgen, maximal androgen blockade, oestrogen). A minimal time window of 1 month is required.
- Medical castration with Testosterone < 50 ng/dl (1.7 nmol/L).
- Metastatic patients before inclusion not considered for targeted therapy.
- Previous treatment with isotopes (Radium, Samarium, Strontium, etc.)
- All medical conditions that might interfere with the correct performance of imaging scans.
- Known allergy/sensitivity to 68Ga or HBED-CC coupled substance, or any of the ingredient(s) or excipient(s) of the study medication(s)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single, arm exploratory
Patients will undergo a 68Ga-PSMA PET/CT within 1 month after routine imaging diagnostic work-up.
|
68Ga-PSMA-ligand intravenous administration duration is around one minute.
Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body.
PET/CT images will then be performed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in treatment management are defined as: • Shift to a different therapeutic strategy • Modification of the initial therapeutic strategy • No changes
Time Frame: 2 months
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of positive scans
Time Frame: 2 months
|
|
2 months
|
Correlation of positivity with:
Time Frame: 2 months
|
|
2 months
|
Reference diagnosis
Time Frame: 6 months
|
|
6 months
|
A confirmed PSA response is defined as ≥ 30% reduction of the blood level, compared to the baseline value, confirmed by a second PSA value 4 or more weeks later. PSA responses will be evaluated at for up to 6 months
Time Frame: 6 months
|
6 months
|
|
Androgen Deprivation Therapy (ADT) free survival: time from final Urologic Tumour Board treatment decision to start of ADT treatment during the follow up period of 6 months
Time Frame: 6 months
|
6 months
|
|
Time to prostate specific antigen (PSA) progression according to Prostate Cancer Clinical Trials Working Group criteria
Time Frame: 3 months
|
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Carlos Artigas, MD, Jules Bordet Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IJB-PROS-PROSPERO-2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancers
-
University of Colorado, DenverNational Cancer Institute (NCI)RecruitingProstate Cancer | Head and Neck Cancers | Upper Abdomen CancersUnited States
-
David M. Schuster, MDTerminatedProstate CancersUnited States
-
NucMito Pharmaceuticals Co. Ltd.Recruiting
-
Agenus Inc.CompletedAdvanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1United States
-
Institute of Oncology LjubljanaRecruiting
-
M.D. Anderson Cancer CenterEuropean CommissionCompletedAdvanced CancersUnited States, Spain, France, Israel
-
Aeglea BiotherapeuticsCompletedAdvanced CancersUnited States
-
M.D. Anderson Cancer CenterFoundation MedicineCompleted
-
Hoffmann-La RocheCompletedSolid CancersUnited States, Belgium, France, Spain
-
Hoffmann-La RocheCompleted
Clinical Trials on 68Ga-(HBED-CC)-PSMA
-
Mayo ClinicWithdrawnHepatocellular CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterRecruiting
-
Jonsson Comprehensive Cancer CenterCompletedProstate Adenocarcinoma | Recurrent Prostate CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedBiochemically Recurrent Prostate CarcinomaUnited States
-
German Cancer Research CenterUniversity Hospital Freiburg; ABX CRO; Friedrich-Alexander-Universität Erlangen-NürnbergCompletedProstate Cancer | Prostate Cancer Metastatic | High-risk Prostate Cancer | Lymphnode MetastasisAustria, Germany
-
Mayo ClinicRecruitingAdvanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8United States
-
Jonsson Comprehensive Cancer CenterTerminatedBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8United States
-
Jonsson Comprehensive Cancer CenterTerminatedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8United States
-
Mayo ClinicCompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterCompletedBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | PSA Level Greater Than FiftyUnited States